ABT vs. ASND: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABT and ASND, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ABT dominates in value with a market cap of 231.49 billion USD, eclipsing ASND’s 9.55 billion USD by roughly 24.25×.
ABT’s beta of 0.74 points to much larger expected swings compared to ASND’s calmer 0.40, suggesting both higher upside and downside potential.
ASND is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ABT, which is purely domestic.
Symbol | ABT | ASND |
---|---|---|
Company Name | Abbott Laboratories | Ascendis Pharma A/S |
Country | US | DK |
Sector | Healthcare | Healthcare |
Industry | Medical - Devices | Biotechnology |
CEO | Mr. Robert B. Ford | Mr. Jan Moller Mikkelsen |
Price | 133.05 USD | 158.1 USD |
Market Cap | 231.49 billion USD | 9.55 billion USD |
Beta | 0.74 | 0.40 |
Exchange | NYSE | NASDAQ |
IPO Date | March 17, 1980 | January 28, 2015 |
ADR | No | Yes |
Performance Comparison
This chart compares the performance of ABT and ASND over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ABT and ASND based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ASND shows a negative P/E of -24.55, highlighting a year of losses, whereas ABT at 17.22 trades on solid profitability.
- ASND shows a negative forward PEG of -2.23, signaling expected earnings contraction, while ABT at 1.73 maintains analysts’ projections for stable or improved profits.
- ASND carries a sub-zero price-to-book ratio of -44.20, indicating negative equity. In contrast, ABT (P/B 2.48) has positive book value.
- ASND reports a negative Price-to-Free Cash Flow ratio of -27.43, showing a cash flow shortfall that could threaten its operational sustainability, while ABT at 34.77 maintains positive cash flow.
Symbol | ABT | ASND |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | 17.22 | -24.55 |
Forward PEG Ratio (TTM) | 1.73 | -2.23 |
Price-to-Sales Ratio (P/S, TTM) | 5.47 | 22.89 |
Price-to-Book Ratio (P/B, TTM) | 2.48 | -44.20 |
Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 34.77 | -27.43 |
EV-to-EBITDA (TTM) | 22.97 | -35.74 |
EV-to-Sales (TTM) | 5.63 | 23.78 |
EV-to-Free Cash Flow (TTM) | 35.78 | -28.50 |
Dividend Comparison
ABT delivers a 1.71% dividend yield, blending income with growth, whereas ASND appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
Symbol | ABT | ASND |
---|---|---|
Dividend Yield (TTM) | 1.71% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABT and ASND, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ASND posts a quick ratio of 0.71, indicating limited coverage of short-term debts from its most liquid assets—while ABT at 1.27 enjoys stronger liquidity resilience.
- ASND has negative equity (debt-to-equity ratio -4.46), suggesting asset shortfalls, whereas ABT at 0.14 preserves healthier equity coverage.
- ABT meets its interest obligations (ratio 15.39). In stark contrast, ASND’s negative ratio (-3.72) means its operating earnings (EBIT) don't cover basic operations, let alone interest, signaling serious financial trouble.
Symbol | ABT | ASND |
---|---|---|
Current Ratio (TTM) | 1.78 | 1.04 |
Quick Ratio (TTM) | 1.27 | 0.71 |
Debt-to-Equity Ratio (TTM) | 0.14 | -4.46 |
Debt-to-Assets Ratio (TTM) | 0.16 | 0.80 |
Interest Coverage Ratio (TTM) | 15.39 | -3.72 |